Clinical Studies

Some patients are treated in the IHBT in the framework of clinical studies. Innovative medical products frequently represent the only therapeutic option that can be offered to a patient. For the inclusion in clinical evaluation it is necessary to meet all inclusion conditions, the so-called entry criteria. Before entering clinical evaluation, patients get acquainted in detail with its conditions and course. Involvement in clinical studies is voluntary and the start is bound to the patient’s signature to informed consent. Supervision over clinical evaluation is performed strictly both by the clinical study contractor and other inspecting authorities (a local Ethics Committee, Multi-Centric Ethics Committee, State Institute for Drug Control).

At present more than twenty clinical studies are in progress in the IHBT Clinical Department. They are focused mainly on diseases whose treatment represents core therapeutic programs of the IHBT:

• Myelodysplastic syndrome
• Chronic myeloid leukemia
• Acute myeloid leukemia
• Acute lymphoblastic leukemia
• Hematopoietic cell transplantation
• Idiopathic thrombocytopenic purpura